PARP Inhibition Shows Long-term Survival Benefits for Patients With High-risk, BRCA-positive Breast Cancer in OlympiA Trial - report from SABCS2024

Judy E. Garber, MD, MPH presents updated results of the OlympiA study at San Antonio Breast Cancer Symposium 2024. The new analysis provides further support for olaparib’s benefits in patients with high-risk, HER2-negative breast cancer with germline mutations in BRCA1 or BRCA2. Video: https://medicaldigest.org/scientific-contents/interview:parp-inhibition-shows-long-term-survival-benefits-patients-high-risk-brca-positive-breast-cancer-olympia-trial